Oppenheimer analyst Suraj Kalia downgrades Titan Medical (NASDAQ:TMDI) from Outperform to Perform.
Credit Suisse Maintains Neutral on Centene, Raises Price Target to $75
Credit Suisse analyst Jonathan Yong maintains Centene (NYSE:CNC) with a Neutral and raises the price target from $70 to $75.